Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes

Pharmacogenomics Journal

Volumn 18, Issue 3, 2018, Pages 506-515

  Allegra, S ^a   Cusato, J ^a   De Francia, S ^b   Arduino, A ^a   Longo, F ^b   Pirro, E ^b   Massano, D ^b   De Nicolo A ^a   Piga, A ^b   D'Avolio, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; VITAMIN D; CALCITRIOL RECEPTOR; COLECALCIFEROL 24 HYDROXYLASE; VDR PROTEIN, HUMAN; VITAMIN D BINDING PROTEIN;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; CDX2 GENE; COHORT ANALYSIS; CONTROLLED STUDY; CYP24A1 GENE; CYP27B1 GENE; FEMALE; GC 1296 GENE; GC GENE; GENE; GENE FREQUENCY; GENOTYPING TECHNIQUE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION; VDR GENE; ADOLESCENT; BLOOD; DRUG EFFECT; GENETICS; GENOTYPE; LIVER; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; BETA-THALASSEMIA; DEFERASIROX; FEMALE; GENOTYPE; HUMANS; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; VITAMIN D-BINDING PROTEIN; VITAMIN D3 24-HYDROXYLASE; YOUNG ADULT;

EID: 85047626533     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2017.43     Document Type: Article

References (85)

1. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001; 1: 47-61.
2. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-3462.
3. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102: 17-24.
4. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010; 148: 466-475.
5. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-1602.
6. Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos 2010; 38: 808-816.
7. Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J et al. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 2008; 36: 2523-2538.
8. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T et al. Efficacy and safety of deferasirox doses of 430mg/kg per d in patients with transfusiondependent anaemia and iron overload. Br J Haematol 2009; 147: 752-759.
9. FDA. Exjade (deferasirox) Prescribing Information. Novartis Pharmaceuticals Corporation 2007.
10. Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R et al. ICL670A: preclinical profile. Adv Exp Med Biol 2002; 509: 185-203.
11. Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003; 10: 1065-1076.
12. Galanello R, Origa R. Once-daily oral deferasirox for the treatment of transfusional iron overload. Expert Rev Clin Pharmacol 2008; 1: 231-240.
13. Cappellini MD. Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag 2007; 3: 291-299.
14. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565-572.
15. Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009; 114: 4009-4013.
16. Cusato J, Allegra S, Massano D, De Francia S, Piga A, D'Avolio A. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J 2014; 15: 263-271.
17. Allegra S, Cusato J, Francia SD, Massano D, Piga A, D'Avolio A. Role of pharmacogenetic on deferasirox AUC and efficacy. In: European Society of Human Genetics. Glasgow: 2015.
18. Allegra S, Cusato J, De Francia S, Massano D, Piga A, D'Avolio A. Deferasirox AUC efficacy cutoff and role of pharmacogenetics. Eur J Clin Pharmacol 2016; 72: 1155-1157.
19. Dimitriadou M, Christoforidis A, Fidani L, Economou M, Vlachaki E, Athanassiou-Metaxa M et al. A 2-year prospective densitometric study on the influence of Fok-I gene polymorphism in young patients with thalassaemia major. Osteoporos Int 2015; 27: 781-788.
20. Moulas A, Challa A, Chaliasos N, Lapatsanis PD. Vitamin D metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D) and osteocalcin in beta-thalassaemia. Acta Paediatr 1997; 86: 594-599.
21. Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 2006; 38: 888-892.
22. Wood JC, Claster S, Carson S, Menteer JD, Hofstra T, Khanna R et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Br J Haematol 2008; 141: 891-894.
23. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15-19.
24. Jensen PD. Evaluation of iron overload. Br J Haematol 2004; 124: 697-711.
25. De Francia S, Massano D, Piccione FM, Pirro E, Racca S, Di Carlo F et al. A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 893-894: 127-133.
26. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169: 505-514.
27. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ et al. Linkage disequilibrium in the human genome. Nature 2001; 411: 199-204.
28. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86: 480-487.
29. Thein SL. The molecular basis of beta-thalassemia. Cold Spring Harb Perspect Med 2013; 3: a011700.
30. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373-378.
31. Meier U, Gressner O, Lammert F, Gressner AM. Gc-globulin: roles in response to injury. Clin Chem 2006; 52: 1247-1253.
32. Bouillon R, Xiang DZ, Convents R, Van Baelen H. Polyunsaturated fatty acids decrease the apparent affinity of vitamin D metabolites for human vitamin D-binding protein. J Steroid Biochem Mol Biol 1992; 42: 855-861.
33. Malik S, Fu L, Juras DJ, Karmali M, Wong BY, Gozdzik A et al. Common variants of the vitamin D binding protein gene and adverse health outcomes. Crit Rev Clin Lab Sci 2013; 50: 1-22.
34. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: metabolism. Rheum Dis Clin North Am 2012; 38: 1-11, vii.
35. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96: 507-515.
36. Weisman Y, Harell A, Edelstein S, David M, Spirer Z, Golander A. 1 alpha, 25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature 1979; 281: 317-319.
37. Gray TK, Lester GE, Lorenc RS. Evidence for extra-renal 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in pregnancy. Science 1979; 204: 1311-1313.
38. Stoffels K, Overbergh L, Bouillon R, Mathieu C. Immune regulation of 1alphahydroxylase in murine peritoneal macrophages: unravelling the IFNgamma pathway. J Steroid Biochem Mol Biol 2007; 103: 567-571.
39. Esteban L, Vidal M, Dusso A. 1alpha-Hydroxylase transactivation by gammainterferon in murine macrophages requires enhanced C/EBPbeta expression and activation. J Steroid Biochem Mol Biol 2004; 89-90: 131-137.
40. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys 2011; 523: 9-18.
41. Knutson JC, DeLuca HF. 25-Hydroxyvitamin D3-24-hydroxylase. Subcellular location and properties. Biochemistry 1974; 13: 1543-1548.
42. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998; 78: 1193-1231.
43. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am 2010; 39: 365-379, table of contents.
44. Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 2010; 9: 941-955.
45. Bikle DD. Vitamin D: an ancient hormone. Exp Dermatol 2011; 20: 7-13.
46. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988; 85: 3294-3298.
47. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 2002; 16: 1243-1256.
48. Wood RJ, Tchack L, Angelo G, Pratt RE, Sonna LA. DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics 2004; 17: 122-129.
49. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005; 19: 2685-2695.
50. Fujiki R, Kim MS, Sasaki Y, Yoshimura K, Kitagawa H, Kato S. Ligand-induced transrepression by VDR through association of WSTF with acetylated histones. EMBO J 2005; 24: 3881-3894.
51. Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25 (OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol 2004; 18: 2660-2671.
52. Rebsamen MC, Sun J, Norman AW, Liao JK. 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002; 91: 17-24.
53. Poon AH, Gong L, Brasch-Andersen C, Litonjua AA, Raby BA, Hamid Q et al. Very important pharmacogene summary for VDR. Pharmacogenet Genomics 2012; 22: 758-763.
54. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7: 684-700.
55. Lou YR, Qiao S, Talonpoika R, Syvala H, Tuohimaa P. The role of Vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 317-325.
56. Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2001; 2: 930-942.
57. Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 2010; 70: 1448-1460.
58. Oh JJ, Byun SS, Lee SE, Hong SK, Jeong CW, Choi WS et al. Genetic variants in the CYP24A1 gene are associated with prostate cancer risk and aggressiveness in a Korean study population. Prostate Cancer Prostatic Dis 2014; 17: 149-156.
59. Ramasamy A, Trabzuni D, Forabosco P, Smith C, Walker R, Dillman A et al. Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzyme in multiple sclerosis. Mult Scler Relat Disord 2015; 3: 211-219.
60. Wang Y, Wang O, Li W, Ma L, Ping F, Chen L et al. Variants in Vitamin D binding protein gene are associated with gestational diabetes mellitus. Medicine (Baltimore) 2015; 94: e1693.
61. Hallau J, Hamann L, Schumann RR, Worm M, Heine G. A promoter polymorphism of the vitamin D metabolism gene Cyp24a1 is associated with severe atopic dermatitis in adults. Acta Derm Venereol 2016; 96: 169-172.
62. Bosse Y, Lemire M, Poon AH, Daley D, He JQ, Sandford A et al. Asthma and genes encoding components of the vitamin D pathway. Respir Res 2009; 10: 98.
63. Wjst M. Variants in the vitamin D receptor gene and asthma. BMC Genet 2005; 6: 2.
64. Brehm JM, Schuemann B, Fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS et al. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol 2010; 126: 52-58 e55.
65. Cusato J, Allegra S, Boglione L, De Nicolo A, Baietto L, Cariti G et al. Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. Antivir Ther 2014; 20: 335-341.
66. Cusato J, Allegra S, De Nicolo A, Boglione L, Fatiguso G, Mohamed Abdi A et al. Intracellular and plasma trough concentration and pharmacogenetics of telaprevir. J Pharm Pharm Sci 2015; 18: 171-176.
67. Fatiguso G, Allegra S, Calcagno A, Baietto L, Motta I, Favata F et al. Ethambutol plasma and intracellular pharmacokinetics: a pharmacogenetic study. Int J Pharm 2015; 497: 287-292.
68. Rukin NJ, Strange RC. What are the frequency, distribution, and functional effects of vitamin D receptor polymorphisms as related to cancer risk? Nutr Rev 2007; 65 (8 Pt 2): S96-101.
69. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338: 143-156.
70. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376: 180-188.
71. Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 1997; 11: 1165-1179.
72. Crofts LA, Hancock MS, Morrison NA, Eisman JA. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci USA 1998; 95: 10529-10534.
73. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16: 200-257.
74. Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS et al. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev 2008; 17: 1104-1110.
75. Bikle DD. Vitamin D regulation of immune function. Vitam Horm 2011; 86: 1-21.
76. Jehan F, Gaucher C, Nguyen TM, Walrant-Debray O, Lahlou N, Sinding C et al. Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment. J Clin Endocrinol Metab 2008; 93: 4672-4682.
77. Thirumaran RK, Lamba JK, Kim RB, Urquhart BL, Gregor JC, Chande N et al. Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol 2012; 84: 104-112.
78. Song YH, Naumova AK, Liebhaber SA, Cooke NE. Physical and meiotic mapping of the region of human chromosome 4q11-q13 encompassing the vitamin D binding protein DBP/Gc-globulin and albumin multigene cluster. Genome Res 1999; 9: 581-587.
79. Carpenter TO, Zhang JH, Parra E, Ellis BK, Simpson C, Lee WM et al. Vitamin D binding protein is a key determinant of 25-hydroxyvitamin D levels in infants and toddlers. J Bone Miner Res 2013; 28: 213-221.
80. Wjst M, Altmuller J, Faus-Kessler T, Braig C, Bahnweg M, Andre E. Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res 2006; 7: 60.
81. Anderson LN, Cotterchio M, Cole DE, Knight JA. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev 2011; 20: 1708-1717.
82. Cancado R, Melo MR, de Moraes Bastos R, Santos PC, Guerra-Shinohara EM, Ballas SK et al. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-year Phase 2 study. Eur J Haematol 2015; 95: 545-550.
83. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010; 34: 864-870.
84. Neukirchen J, Fox F, Kundgen A, Nachtkamp K, Strupp C, Haas R et al. Improved survival in MDS patients receiving iron chelation therapy-a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 2012; 36: 1067-1070.
85. Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk Res 2012; 36: 1380-1386.